Duality Advisers, LP Denali Therapeutics Inc. Transaction History

Duality Advisers, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 03, 2022	BUY	$25.97 - $38.53 $512,336 - $760,119	19,728 New	19,728 $605,000
Q2 2022 Aug 08, 2022	SELL	$20.88 - $35.19 $714,096 - $1.2 Million	-34,200 Closed	0 $0
Q1 2022 May 09, 2022	BUY	$29.0 - $47.27 $991,800 - $1.62 Million	34,200 New	34,200 $1.1 Million
Q4 2021 Feb 02, 2022	SELL	$42.59 - $55.02 $981,486 - $1.27 Million	-23,045 Closed	0 $0
Q3 2021 Nov 08, 2021	BUY	$48.48 - $78.23 $1.12 Million - $1.8 Million	23,045 New	23,045 $1.16 Million
Q2 2021 Aug 09, 2021	SELL	$50.3 - $78.44 $987,992 - $1.54 Million	-19,642 Closed	0 $0
Q1 2021 May 13, 2021	BUY	$53.8 - $81.53 $1.06 Million - $1.6 Million	19,642 New	19,642 $1.12 Million

227

119M

60.6K

48.4K

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $2.88B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

Get notified when there are updates to the investment portfolio of Duality Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Duality Advisers, LP with notifications on news.